Impact of sodium glucose co-transporter-2 inhibitors on left atrial functions in patients with type-2 diabetes and heart failure with mildly reduced ejection fraction.

BACKGROUND

We aimed to assess the impact of adding sodium glucose co-transporters-2 inhibitors (SGLT-2I) on cardiac remodeling in type 2 diabetic patients with heart failure with mildly reduced ejection fraction (HFmrEF) that had been under-represented in most clinical trials through the analysis of left atrial (LA) phasic functions with 2-D speckle tracking echocardiography (2D- STE.

METHODS

We enrolled 70 patients with type 2 diabetes (T2DM) and stable HFmrEF (35 patients received one of SGLT-2I either empagliflozin or dapagliflozin). Laboratory assessment and echocardiographic evaluation were carried out at baseline and after 6 months. LA volumes and deformation analysis were conducted using 2D-STE. Three LA strain parameters were obtained (LA reservoir strain, contractile strain, and conduit strain).

RESULTS

After 6 months of SGLT-2 I treatment, there was better control of HbA1C and improvement of diastolic functions (E/e' ratio and LAV-I significantly decreased. P < 0.001*). LVGLS increased, LA functions and all LA strain curve values improved, LA reservoir increased from 17.3 ± 2.0 to 23.8 ± 3.6, LA conduit from 11.0 ± 2.2 to 13.7 ± 2.8 and LA contractile from 6.5 ± 1.4 to 10.5 ± 2.6, P < 0.001* for all. Changes in LA strain values were significantly associated with the changes in LVGLS, LAEF %, E/ e' ratio, and LAV-I.

CONCLUSION

Adding SGLT-2I to existing guideline-directed medical therapy in patients with T2DM and HFmrEF is associated with favorable clinical outcomes and significant improvement of LA volume and functions, with further improvement of LV diastolic and longitudinal functions.